Clinical Trial Update: Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy, safety, and tolerability of levomilnacipran ER in pediatric patients (7-17) with major depressive disorder has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Levomilnacipran ER (levomilnacipran hydrochloride)

Snippet

Sponsor: Allergan | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2022-03-25